Metformin reduces the stimulatory effect of obesity on in vivo Walker-256 tumor development and increases the area of tumor necrosis


Autoria(s): FONSECA, Eveline Aparecida Isquierdo; OLIVEIRA, Maria Aparecida de; LOBATO, Nubia de Souza; AKAMINE, Eliana Hiromi; COLQUHOUN, Alison; CARVALHO, Maria Helena Catelli de; ZYNGIER, Szulim Ber; FORTES, Zuleica Bruno
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2011

Resumo

Aims: The objective of this study was to analyze the influence of obesity and insulin resistance on tumor development and, in turn, the effect of insulin sensitizing agents. Main methods: Male offspring of Wistar rats received monosodium glutamate (400 mg/kg) (obese) or saline (control) from the second to sixth day after birth. Sixteen-week-old control and obese rats received 5 x 10(5) Walker-256 tumor cells, subcutaneously injected into the right flank. Some of the obese and control rats received concomitant treatment with metformin (300 mg/kg) by gavage. At the 18th week, obesity was characterized. The percentage of rats that developed tumors, the tumor relative weight and the percentage of cachexia incidence were analyzed. The tumor tissue was evaluated histologically by means of hematoxylin and eosin staining. Key findings: Metformin did not correct the insulin resistance in obese rats. The tumor development was significantly higher in the obese group, whereas metformin treatment reduced it. After pathological analysis, we observed that the tumor tissues were similar in all groups except for adipocytes, which were found in greater quantity in the obese and metformin-treated obese groups. The area of tumor necrosis was higher in the group treated with metformin when compared with the untreated one. Significance: Metformin reduced Walker-256 tumor development but not cachexia in obese rats. The reduction occurred independently of the correction of insulin resistance. Metformin increased the area of necrosis in tumor tissues, which may have contributed to the reduced tumor development. (C) 2011 Elsevier Inc. All rights reserved.

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Instituto Nacional de Ciencias e Tecnologia (INCT) of Obesity and Diabetes/CNPq

Identificador

LIFE SCIENCES, v.88, n.19-20, p.846-852, 2011

0024-3205

http://producao.usp.br/handle/BDPI/28140

10.1016/j.lfs.2011.03.005

http://dx.doi.org/10.1016/j.lfs.2011.03.005

Idioma(s)

eng

Publicador

PERGAMON-ELSEVIER SCIENCE LTD

Relação

Life Sciences

Direitos

restrictedAccess

Copyright PERGAMON-ELSEVIER SCIENCE LTD

Palavras-Chave #Metformin #Obesity #Insulin resistance #Cancer #Tumor necrosis #INSULIN-RESISTANCE #DIABETIC-PATIENTS #PROTEIN-KINASE #CANCER CELLS #GROWTH #CACHEXIA #COMBINATION #INHIBITOR #EPIDEMIC #ANOREXIA #Medicine, Research & Experimental #Pharmacology & Pharmacy
Tipo

article

original article

publishedVersion